⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
accessnewswire.com
LEXX
NVO
LLY
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
globenewswire.com
NVO
Planisware unveils latest AI innovations at its annual Exchange26 EMEA conference
globenewswire.com
NVO
Parker Waichman LLP Files Lawsuit on behalf of Massachusetts Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy
prnewswire.com
NVO
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
prnewswire.com
NVO
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
globenewswire.com
NVO
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
globenewswire.com
NVO